Correlation between Adverse Events and Antibody Titers among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 Vaccine
Authors:
- Itzchak LevyItzchak Levy
- Einav Gal LevinELEinav Gal Levin
- Liraz OlmerLOLiraz Olmer
- Gili Regev-YochayGRGili Regev-Yochay
- Nancy Agmon-LevinNancy Agmon-Levin
- Anat Wieder-FinesodAWAnat Wieder-Finesod
- Victoria IndenbaumVIVictoria Indenbaum
- Karin HerzogKHKarin Herzog
- Ram DoolmanRDRam Doolman
- Keren AsrafKAKeren Asraf
- Rebecca HalperinRHRebecca Halperin
- Yaniv LustigYLYaniv Lustig
Open Access
Abstract
Objectives: The BNT162b2 mRNA COVID-19 vaccine has been found to be highly effective in preventing COVID-19 but is associated with increased reactogenicity. We aimed to examine the correlation between immunogenicity and reactogenicity of the BNT162b2 vaccine. Methods: Subjects without prior SARS-CoV-2 infection that participated in active surveillance after being vaccinated with the BNT162b2 vaccine were included. Study participants reported adverse drug reactions (ADRs) through questionnaires administered by text message after receiving each dose of the vaccine. A reactogenicity score was developed based on the type and duration of ADRs. In addition, anti-receptor binding domain (RBD) levels and neutralization assays were performed 7–21 and 7–38 days after the first and second vaccine doses, respectively. Associations between ADRs and antibody levels were assessed by Spearman correlations. Multivariable logistic regression analyses were used to identify factors associated with ADRs. Results: A total of 831 health care workers were included. The mean age was 46.5 years (SD = 11.8) and 75.5% were females. 83.4% and 83.3% had at least one local ADR after the first and second doses, respectively. 33% and 83.2% had at least one systemic ADR after the first and second doses, respectively. Multivariate logistic regression analysis found a significant correlation between ADR score and anti-RBD-IgG titers (r = 0.366; p < 0.0001) after adjustment for age, gender, and days after the second vaccination. High anti-RBD-IgG levels, being younger than 55 and being female, were all correlated with increased rates of ADRs. Conclusion: BNT162b2 mRNA COVID-19 vaccine reactogenicity appears to be correlated with higher post-vaccination antibody levels and is independently associated with younger age and female gender.Keywords
This publication has 29 references indexed in Scilit:
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineNew England Journal of Medicine, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- I mmunosenescence and Inflammaging: Risk Factors of Severe COVID-19 in Older PeopleFrontiers in Immunology, 2020
- Age-Associated B CellsAnnual Review of Immunology, 2020
- The how’s and what’s of vaccine reactogenicitynpj Vaccines, 2019
- Sex differences in vaccine-induced humoral immunitySeminars in Immunopathology, 2018
- Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence from 2000 to 2017 in Those Aged 65 and Over in England and WaleseClinicalMedicine, 2018
- The life cycle of a T cell after vaccination – where does immune ageing strike?Clinical and Experimental Immunology, 2016
- Sex-based Biology and the Rational Design of Influenza Vaccination StrategiesThe Journal of Infectious Diseases, 2014
- Efficacy and effectiveness of influenza vaccines in elderly people: a systematic reviewThe Lancet, 2005